1. Scrip
  2. >>Advanced Therapies

Vertex/CRISPR Prepare To Take Exa-Cel To Regulators For SCD, TDT

 
• By Alaric DeArment

The first gene-edited therapy will be submitted for sickle cell disease and transfusion-dependent beta thalassemia; it will compete with bluebird in both indications, but analysts anticipate blockbuster sales in excess of $2bn.

Vertex and CRISPR plan to start a rolling submission of exa-cel, previously CTX001, in SCD and TDT in November • Source: Shutterstock

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG’s submission plans for exagamglogene autotemcel (exa-cel) in sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) will likely place it neck-and-neck with competitor bluebird bio’s investigational gene therapy for SCD, not to mention its approved TDT therapy. Analysts anticipate approval, successful launch and blockbuster sales.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gene Therapies

More from Advanced Therapies